Immunomodulating agents and the transplant situation

Drug-Induced Liver Disease

Volumn , Issue , 2002, Pages 633-652

  Hebert, Mary F ^a   Taylor, Shari L ^b   Carithers, Robert L ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GI Pathology Partners   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3142620651     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (119)

1. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22:947-955.
2. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Pharmacol 1992; 21:511-526.
3. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ, et al. Cytochrome P-450 hPCN3 a novel cytochrome P-450 IIIA gene product that is differentially expressed in human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264:10388-10395.
4. Sattler M, Guengerich FD, Yun C-H, Christians U, Sewing K-F. Cytochrome p-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20:153-761.
5. Lown KS, Mayo RR, Leichtman AB, Hsiano HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal p-glycoprotein (mdr 1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62:248-260.
6. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human p-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268:6077-6080.
7. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprineallopurinol interaction after heart and lung transplantation. Transplantation 1996; 61:1661-1662.
8. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996; 30:951-954.
9. Watts RWE, Watts JEM, Seegmiller JE. Xanthine oxidase activity in human tissues and its inhibition by allopurinol. J Lab Clin Med 1965; 66:688-697.
10. Zimm S, Collins JM, O’Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983; 34:810-816.
11. Roche Laboratories Inc. CellCept, mycophenolate mofetil package insert, Nutley, 1998:1:12.
12. Anuras S, Piros J, Bonney WW, Forker EL, Colville DS, Corry RJ. Liver disease in renal transplant recipients. Arch Intern Med 1977; 137:42-48.
13. Horina JH, Wirnsberger GH, Kenner L, Holzer H, Krejs GJ. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation 1993; 56:1091-1094.
14. Degos F, Degott C, Bedrossian J, Camilieri JP, Barbanel C, Duboust A, Rueff B, Benhamou JP, Kreis H. Is renal transplantation involved in post-transplantation liver disease? A prospective study. Transplantation 1980; 29:100-102.
15. Delgado J, Munoz de Bustillo E, Ibarrola C, Colina F, Morales JM, Rodriguez E, Aguado JM, Fuertes A, Gomez MA. Is azathioprine a contributory factor? J Heart Lung Transplant 1999; 18:607-610.
16. Hill RB, Droke WE, Hays AP. Hepatic lipid metabolism in the cortisone-treated rat. Exp Mol Pathol 1965; 4:320-327.
17. Jeanrenaud B. Effect of glucocorticoid hormones on fatty acid mobilization and reesterification in rat adipose and tissue. Biochem J 1967; 103:627-633.
18. Bhagwat AG, Deodhar SD. Experimental hepatic injury produced in the rabbit by glucocorticoids. Arch Pathol 1968; 85:346-356.
19. Popper H. Morphologic and biochemical aspects of fatty liver. Acta Hepto Splenolog 1961; 8:279-292.
20. Soffer LJ, Iannaccone A, Gabrilove JL. Cushing’s syndrome: study of fifty patients. Am J Med 1961; 30:129-146.
21. Steinberg H, Webb WM, Rafsky HA. Hepatomegaly with fatty infiltration secondary to cortisone therapy: case report. Gastroenterology 1952; 21:304-309.
22. Stollerman GH. Rheumatic fever. Arch Intern Med 1956; 98:211-220.
23. Hill RB. Fatal fat embolism from steroid-induced fatty liver. N Engl J Med. 1961; 265:318-320.
24. Jones JP, Engleman EP, Najarian JS. Systemic fat embolism after renal homotransplantation and treatment with corticosteroids. N Engl J Med 1965; 273:1453-1458.
25. Zucher RM, Frey BM, Frey FJ. Impact of ketoconazole on metabolism of prednisolone. Clin Pharmacol Ther 1989; 45:366-372.
26. Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 1983; 56:702-709.
27. Legler UF, Benet LZ. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. Clin Pharmacol Ther 1986; 39:425-429.
28. Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM, Lemann J. Interaction of rifampin and glucocorticoids. JAMA 1976; 236:1958-1960.
29. Hendrickse W, McKiernan J, Pickup M, Lowe J. Rifampicin-induced nonresponsiveness to corticosteroid treatment in nephrotic syndrome. Br Med J 1979; 1:306.
30. Ohnhaus EE, Park BK. Measurement of urinary 6-ß-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 1979; 15:139-145.
31. Choi Y, Thrasher K, Werk EE, Sholiton LJ, Olinger C. Effect of diphenylhydantoin on cortisol kinetics in humans. J Pharmacol Exp Ther 1971; 176:27-34.
32. Ramalho HJ, Terra EG, Cartapatti E, Barberato JB, Alves VAF, Gayotto LCC, Abbud-Filho M. Hepatotoxicity of azathioprine in renal transplant recipients. Transplant Proc 1989; 21: 1716-1717.
33. Sparberg M, Simon N, Del Greco F. Intrahepatic cholestasis due to azathioprine. Gastroenterology 1969; 57:439-441.
34. Zarday Z, Veith FJ, Gliedman ML, Soberman R. Irreversible liver damage after azathioprine. JAMA 1972; 222:690-691.
35. Hankey GJ, Saker BM. Peliosis hepatis in a renal transplant recipient and in a haemodialysis patient. Med J Aust 1987; 146:102-105.
36. Haboubi NY, Ali HH, Whitwell HL, Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988; 83:256-261.
37. Eisenhauer T, Hartmenn H, Rumpf KW, Helmchen U, Scheler F, Creutzfeldt W. Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt. Digestion 1984; 30:185-190.
38. Jones MC, Best PV, Catto GRD. Is nodular regenerative hyperplasia of the liver associated with azathioprine therapy after renal transplantation? Nephrol Dial Transplant 1988; 3:331-333.
39. Small P, Lichter M. Probable azathioprine hepatotoxicity: a case report. Ann Allergy 1989; 62:518-520.
40. Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD. Azathioprine and hepatic venoocclusive disease in renal transplant patients. Gastroenterology 1986; 90:446-454.
41. Read AE, Wiesner RH, LaBrecque DR, Tifft JG, Mullen KD, Sheer RL, Petrelli M, Ricanati ES, McCullough AJ. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986; 104:651-655.
42. Sterneck M, Wiesner RH., Ascher N, Roberts J, Ferrell L, Ludwig J, Lake J. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14:806-810.
43. Weitz H, Gokel JM, Loeschke K, Possinger K, Eder M. Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Arch 1982; 395:245-256.
44. Buffet C, Cantarovitch M, Pelletier G, Fabre M, Martin E, Charpentier B, Etienne JP, Fries D. Three cases of nodular regenerative hyperplasia of the liver following renal transplantation. Nephrol Dial Transplant 1988; 3:327-330.
45. Duvoux C, Kracht M, Lang P, Vernant J-P, Safrani E-S, Dhumeaux D. Hyperplasie nodulaire regenerative du foie associee a la prise d’azathioprine. Gastroenterol Clin Biol 1991; 15: 968-973.
46. Marubbio AT, Danielson B. Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine. Gastroenterology 1975; 69:739-743.
47. DePinho RA, Goldberg CS, Lefkowitch JH. Azathioprine and the liver, evidence favoring idosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology 1984; 86: 162-165.
48. Lin S-N, Jessup K, Floyd M, Wang TP, van Buren CT, Caprioli RM, Kahan BD. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients. Transplantation 1980; 29:290-294.
49. Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Tufveson G, Grefberg N. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. Int J Immunopharmacol 1986; 8:1-11.
50. Lennard L, Brown CB, Fox M, Maddocks JL. Azathioprine metabolism in kidney transplant recipients. Br J Clin Pharmacol 1984; 18:693-700.
51. Chan GLC, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30:358-363.
52. Lennard L, Maddocks JL. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine in human red blood cells. J Pharm Pharmacol 1983; 35:15-18.
53. Elion GB, Callahan S, Nathan H, Bieber S, Rundles RW, Hitchings GH. Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. Biochem Pharmacol 1963; 12:85-93.
54. Bergan S, Rugstad HE, Bentadal O, Stokke O. Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes. Transplantation 1994; 58:803-808.
55. Lennard L, Harrington CI, Wood M, Maddocks JL. Metabolism of azathioprine to 6-thio-guanine nucleotides in patients with pemphigus vulgaris. Br J Clin Pharmacol 1987; 23:229-233.
56. Remy CN. Metabolism of thiopyrimidines and thiopurines: S-methylation and S-adenosyl-methionine transmethylase and catabolism in mammalian tissue. J Biol Chem 1963; 238: 1078-1084.
57. Woodson LC, Weinshilbaum RM. Human kidney thiopurine methyltransferase: Purification and biochemical properties. Biochem Pharmacol 1983; 32:819-826.
58. Philips FS, Sternberg SS, Hamilton L, Clarke DA. The toxic effects of 6-mercaptopurine and related compounds. Ann NY Acad Sci 1954; 60:283-296.
59. Gross R. Hepatotoxicity of 6-mercaptopurine and azathioprine. Mayo Clin Proc 1994; 69: 498-500.
60. Einhorn M, Davidsohn I. Hepatotoxicity of mercaptopurine. JAMA 1964; 188:802-806.
61. Clark PA, Hsia YE, Huntsman RG. Toxic complications of treatment with 6-mercaptopurine, two cases with hepatic necrosis and intestinal ulceration. Br Med J 1960; 1:383-395.
62. McIlvanie SK, MacCarthy JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 1958; 14:80-90.
63. Shorey J, Schenker S. Hepatotoxicity of mercaptopurine. Arch Intern Med 1968; 122:5458.
64. Minow RA, Stern MH, Casey JH, Rodriguez V, Luna MA. Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and adriamycin. Cancer 1976; 38: 1524-1528.
65. Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia, report of two cases. Ann Intern Med 1976; 85:578-582.
66. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocro-taline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23:589-599.
67. Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy: a morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine 1980; 59:367-379.
68. Mourad G, Bories P, Berthelemy C, Barneon G, Michel H, Mion C. Peliosis hepatis and nodular regenerative hyperplasia of the liver in renal transplants: is cytomegalovirus the cause of this severe disease? Transplant Proc 1987; 19:3697-3698.
69. Klintmalm GBG, Iwatsuki S, Starzl TE. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 1981; 32:488-489.
70. Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. Liver injury from cyclosporine A. Dig Dis Sci 1990; 35:693-697.
71. Atkinson K, Biggs J, Dodds A, Concannon A. Cyclosporin-associated hepatotoxicity after allogeneic marrow transplantation in man: differentiation from other causes of post transplant liver disease. Transplant Proc 1983; 15:s2761-2767.
72. McKenzie FN, Moses GC, Henderson AR. Routine “cardiac” and “hepatic” serum enzyme profiles in cardiac transplant patients treated with cyclosporine A: operative and postoperative findings. Clin Chem 1985; 31:822-825.
73. Laupacis A, Keown PA, Ulan RA, Sinclair NR, Stiller CR. Hyperbilirubinemia and cyclosporin A levels. Lancet 1981; 2:1426-1427.
74. Schade RR, Guglielmi A, Van Thiel DH, Thompson ME, Warty V, Griffith B, Sanghvi A, Bahnson H, Hardesty R. Cholestasis in heart transplant recipients treated with cyclosporine. Transplant Proc 1983; 15:2757-2760.
75. Loertscher R, Wenk M, Harder F, Brunner F, Follath F, Thiel G. Hyperbilirubinemia and cyclosporin A levels in renal transplant patients. Lancet 1981; 2:635-636.
76. Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, Van Buren CT. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center from one to five years. Transplantation 1987; 43:197-204.
77. Lorber MI, Van Buren CT, Flechner SM, Williams C, Kahan BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 1987; 43:35-40.
78. Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A, Jimenez R. Inhibition of hepato-cytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology 1990; 12:83-91.
79. Stone BG, Udani M, Sanghvi A, Warty V, Plocki K, Bedetti CD, Van Thiel DH. Cyclosporin A-induced cholestasis: the mechanism in a rat model. Gastroenterology 1987; 93:344-351.
80. Rotolo FS, Branum GD, Bowers BA, Meyers WC. Effect of cyclosporine on bile secretion in rats. Am J Surg 1986; 151:35-40.
81. Cadranel JF, Dumont M, Mesa VA, Degott C, Touchard D, Erlinger S. Effect of chronic administration of cyclosporin A on hepatic uptake and biliary secretion of bromosulfoph-thalein in rat. Dig Dis Sci 1991; 36:221-224.
82. Nicchitta CV, Kamoun M, Williamson JR. Cyclosporin augments receptor-mediated cellular Ca fluxes in isolated hepatocytes. J Biol Chem 1985; 260:13613-13618.
83. Stacey NH, Kotecka B. Inhibition of taurocholate and ouabain transport in isolated rat hepatocytes by cyclosporin A. Gastroenterology 1988; 95:780-786.
84. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM, Young JB. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262:53-56.
85. Drueke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991; 31(suppl):24-28.
86. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994; 57: 1479-1483.
87. Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7a-hydroxylase, LDL receptor, HDL receptor, VLDL receptor and lipoprotein lipase expressions. J Pharmacol Exp Ther 2000; 294:778-783.
88. Rayyes OA, Wallmark A, Floren CH. Cyclosporine inhibits catabolism of low-density lipoproteins HepG2 cells by about 25%. Hepatology 1996; 24:613-619.
89. Wisecarver JL, Earl RA, Haven MC, Timmins PW, Shaw BW, Stratta RJ, Langnas AN, Zetterman RK, Donovan JP, Shaefer MS, Markin RS. Histologic changes in liver allograft biopsies associated with elevated whole blood and tissue cyclosporine concentrations. Modern Pathol 1992; 5:611-616.
90. Lowell JA, Stratta RJ, Taylor RJ, Bynon JS, Larsen JL, Nelson NL. Cholelithiasis in pancreas and kidney transplant recipients with diabetes. Surgery 1993; 114:863-864.
91. Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725-1738.
92. Whiting PH, Simpson JG, Davidson RJL, Thomson AW. Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks. Br J Exp Pathol 1983; 64:437-444.
93. Farthing MJG, Clark ML. Nature of the toxicity of cyclosporin A in the rat. Biochem Pharmacol 1981; 30:3311-3316.
94. Calne RY, White DJG, Pentlow BD, Rolles DK, Syrakos T, Ohtawa T, Smith DP, McMaster P, Evans DB, Herbertson BM, Thiru S. Cyclosporin A: Preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc 1979; 11:860-864.
95. Steck TB, Costanzo-Nordin MR, Keshavarizian A. Prevalence and management of cholelithiasis in heart transplant patients. J Heart Lung Transplant 1991; 10:1029-1032.
96. Mathieu P, Carrier M, White M, Pellerin M, Perrault LP, Pelletier G, Pelletier LC. Conversion of cyclosporine A to tacrolimus following heart transplantation. Can J Cardiol 1999; 15: 1229-1232.
97. Kowdley KV, Keeffe EB. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am 1995; 24:991-1001.
98. Maurer G, Loosli HR, Schreier E, Keller B. Disposition of cyclosporin in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos 1984; 12: 120-126.
99. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporin and its metabolites. Transplant Proc 1986; 18:25-34.
100. Christians U, Schlitt HJ, Bleck JS, Schiebel HM, Kownatzki R, Maurer G, Strohmeyer SS, Schottmann R, Wonigeit K, Pichlmayr R, Sewing KF. Measurement of cyclosporine and 18 metabolites in blood, bile and urine by high-performance liquid chromatography (HPLC). Transplant Proc 1988; 20:609-613.
101. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing K-F. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23:1315-1324.
102. Naito M, Tsuruo T. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 1989; 49:1452-1455.
103. Fisher A, Mor E, Hytiroglou P, Emre S, Boccagni P, Chadoff L, Sheiner P, Schwartz M, Thung SN, Miller C. FK506 hepatotoxicity in liver allograft recipients. Transplantation 1995; 59:1631-1632.
104. Tsamandas AC, Jain AB, Felekouras ES, Fung JJ, Demetris AJ, Lee RG. Central venulitis in the allograft liver. Transplantation 1997; 64:252-257.
105. Wyeth-Ayerst Pharmaceuticals. Rapamune (sirolimus) oral solution product labeling. Philadelphia, 2000:1-4.
106. Nicolau DP, Uber WE, Crumbley AJ, Strange C. Amiodarone-cyclosporine interaction in heart transplant patient. J Heart Lung Transplant 1992; 11:564-568.
107. Gersema LM, Proter CB, Russell EH. Suspected drug interaction between cyclosporine and clarithromycin. J Heart Lung Transplant 1994; 13:343-345.
108. Neumayer HH, Wagner K. Diltiazem and economic use of cyclosporin. Lancet 1986; 2:523.
109. Gupta SK, Bakran A, Johnson RWG, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27:475-481.
110. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharma-cother 1993; 27:427-430.
111. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57:485-491.
112. Trenk D, Brett W, Jahnchen E, Birnbaum D. Time course of cyclosporin/itraconazole interaction. Lancet 1987; 2:1335-1336.
113. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58:15-19.
114. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52:453-457.
115. Sketris IS, Methot ME, Nicol D, Belitsky P, Knox MG. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994; 28: 1227-1231.
116. Bourbigot B, Guiserix J, Airiau J, Bressollette L, Morin JF, Cledes J. Nicardipine increases cyclosporin blood levels. Lancet 1986; 1:1447.
117. Cooney GF, Mochon M, Kaiser B, Dunn SP, Goldsmith B. Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. Pharmacotherapy 1995; 15: 353-356.
118. Carstensen H, Jacobsen N, Dieperink H. Interaction between cyclosporin A and phenobarbi-tone. Br J Clin Pharmacol 1986; 21:550-551.
119. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 1984; 18:887-893.